Mutations in 11 genes (EGFR, KRAS, ALK, ROS1, BRAF, NTRK1, NTRK2, NTRK3, MET, RET, ERBB2), IHC quantified PD-L1 (CD274) expression, microsatellite instability, and Tumor Mutation Burden (TMB) constitute the FDA recognized predictive biomarkers predicting response to NSCLC therapies (Table S1A; Figure 3B). The gene discussed is BRAF; the disease is neoplasm.